Author
Unnikrishnan is currently Senior Associate Editor with BW Businessworld at its Mumbai Bureau. During his two decades long journalistic career, he has received several media awards and recognitions. His articles on healthcare, life sciences and intellectual property rights (IPR) have been republished by several international blogs and journals.
The latest investment supports the growth of business-to-consumers e-commerce in India, and is part of the company’s broader plan to aggressively expand across Asia Pacific
Read More
Mistry replaced by Harish Bhat, a non-executive director of Tata Global Beverages; Mistry calls the move illegal
Read More
For Ratan Tata, the challenges are mounting. Coming back from retirement to take over the reins of a major holding company which manages billions of dollars in revenue is no easy task
Read More
Professional educational institutions including IIMs have started professional management programmes that are tailor-made for the fast growing healthcare industry
Read More
UK Prime Minister Theresa May’s first trade mission to India is seen as critically important for both the countries as UK currently looks beyond Europe and India’s fastest economic growth is forecasted to continue in 2017 and 2018
Read More
Finnish retail major Stockmann has signed a five-year cooperation agreement with Tech Mahindra to produce part of Stockmann’s information and communications technology services
Read More
The Tata Sons board gives its Chairman complete autonomy to manage opportunities and challenges. However, the tenure of the former Chairman was marked by repeated departures from the culture and ethos of the group
Read More
Experts say since the group’s preferences would now naturally be a candidate who believes in the values that made the group different from its rivals and most preferably from the Tata legacy itself rather than a new-age professional who sticks to ‘profitability’ alone, the selection process is going to be a complex one
Read More
K. Anand, CEO and managing director, Qualiminds, tells BW Businessworld that the pharmaceutical industry’s attitude to compliance with regulatory norms has to change
Read More
Indian pharma companies have had to pay a heavy cost for non-compliance with US FDA regulations and post-ban remedial measures using pricey foreign consultants unfamiliar with the country. Now, help is available locally and at a much cheaper cost
Read More
